FDA/CDER and AASLD 2021 DILI Conference XVIII

Virtual Conference: Hepatotoxicity related to pharmaceutical drugs, biological agents, and dietary supplements from a clinical, non-clinical, and post-marketing perspective.

Poster Presentations:

• Assessing the Potential for Hepatotoxicity for Combination Therapy of Valproate (VPA) and (CBD) using Quantitative Systems Toxicology (QST)
• Quantitative systems toxicology (QST) to investigate mechanisms contributing to clinical bilirubin elevations
• Quantitative Systems Toxicology Modeling Using DILIsym Suggests That Drug-Induced Liver Injury Can Be Enhanced by Co-administered Drugs and Mitigated by Mitochondrial Biogenesis

Session Presentations:

Wednesday, April 21, 2021 –

• Paul Watkins (and William Proctor) will be the moderate Session III: Innovative Tools to Predict and Diagnose DILI. During this session James Beaudoin will present, Quantitative Systems Modeling: Can it Predict Disease-Related DILI Risk? from 9:10 – 9:30 AM EDT.
• Paul Watkins will present during Session IV: Cancer Drugs & Hepatotoxicity, CTCAE Grading and Other Approaches to Measure DILI Severity: What Makes Sense? from 11:30-11:50 AM EDT.

Conference details:

https://www.fda.gov/drugs/news-events-human-drugs/fdacder-and-aasld-2021-dili-conference-xviii-04202021-04222021

https://www.aasld.org/event/aasld-fda-dili-conference